Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis

Thrombosis Research

Volumn 120, Issue 3, 2007, Pages 371-379

  Eilertsen, Anette Løken ^a   Sandvik, Leiv ^a   Mowinckel, Marie Christine ^a   Andersen, Trine Opstad ^a   Qvigstad, Erik ^a   Sandset, Per Morten ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Coagulation factors; Coagulation inhibitors; Fibrinolytic factors; Hormone therapy; Raloxifene; Tibolone

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING INHIBITOR; ESTRADIOL PLUS NORETHISTERONE ACETATE; FIBRINOLYTIC FACTOR; PROTEIN C; PROTEIN S; RALOXIFENE; TIBOLONE; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MECHANISM; FEMALE; FIBRINOLYSIS; HORMONAL THERAPY; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 34249947137     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2006.10.013     Document Type: Article

References (29)

1. Lowe G.D.O. Hormone replacement therapy and cardiovascular disease: increased risks of venous thromboembolism and stroke, and no protection from coronary heart disease. J Intern Med 256 5 (2004) 361-374
2. Peverill R.E. Hormone therapy and venous thromboembolism. Best Pract Res Clin Endocrinol Metab 17 1 (Mar 2003) 149-164
3. Koh K.K., Horne III M.K., and Cannon III R.O. Effects of hormone replacement therapy on coagulation, fibrinolysis, and thrombosis risk in postmenopausal women. Thromb Haemost 82 2 (Aug 1999) 626-633
4. Kroon U.B., Silfverstolpe G., and Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemost 71 4 (Apr 1994) 420-423
5. Teede H.J., McGrath B.P., Smolich J.J., Malan E., Kotsopoulos D., Liang Y.L., et al. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arterioscler Thromb Vasc Biol 20 5 (May 1 2000) 1404-1409
6. van Baal W.M., Emeis J.J., van der Mooren M.J., Kessel H., Kenemans P., and Stehouwer C.D. Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study. Thromb Haemost 83 1 (Jan 2000) 29-34
7. Vehkavaara S., Silveira A., Hakala-Ala-Pietila T., Virkamaki A., Hovatta O., Hamsten A., et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 85 4 (Apr 2001) 619-625
8. Scarabin P.Y., Alhenc-Gelas M., Taisne P., Agher R., and Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: a randomized controlled trial. Arterioscler Thromb Vasc Biol 17 11 (Nov 1 1997) 3071-3078
9. Caine Y.G., Bauer K.A., Barzegar S., ten C.H., Sacks F.M., Walsh B.W., et al. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost 68 4 (Oct 5 1992) 392-395
10. Hoibraaten E., Qvigstad E., Andersen T.O., Mowinckel M.C., and Sandset P.M. The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism-results from a randomized, double-blind, clinical trial. Thromb Haemost 85 5 (May 2001) 775-781
11. Mann K.G., Brummel K., and Butenas S. What is all that thrombin for?. J Thromb Haemost 1 7 (Jul 2003) 1504-1514
12. Eilertsen A.L., Qvigstad E., Andersen T.O., Sandvik L., and Sandset P.M. Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation. Maturitas 55 3 (Oct 20 2006) 278-287
13. Bendz B., Andersen T.O., and Sandset P.M. A new sensitive chromogenic substrate assay of tissue factor pathway inhibitor type 1. Thromb Res 97 6 (Mar 15 2000) 463-472
14. Winkler U.H., Altkemper R., Kwee B., Helmond F.A., and Coelingh Bennink H.J.T. Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomized study. Fertil Steril 74 1 (Jul 2000) 10-19
15. Norris L.A., Joyce M., O'Keeffe N., Sheppard B.L., and Bonnar J. Haemostatic risk factors in healthy postmenopausal women taking hormone replacement therapy. Maturitas 43 2 (Oct 25 2002) 125-133
16. Ng M.K., Quinn C.M., McCrohon J.A., Nakhla S., Jessup W., Handelsman D.J., et al. Androgens up-regulate atherosclerosis-related genes in macrophages from males but not females: molecular insights into gender differences in atherosclerosis. J Am Coll Cardiol 42 7 (Oct 1 2003) 1306-1313
17. Vogelvang T.E., Mijatovic V., Kenemans P., Emeis J.J., Heijst J.A., and van der Mooren M.J. The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: a randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women. Am J Obstet Gynecol 193 4 (Oct 2005) 1384-1394
18. Azevedo G.D., Franco R.F., Baggio M.S., Maranhao T.M., Ferriani R.A., and Silva de Sa M.F. Effects of raloxifene therapy on the anticoagulant system in postmenopausal women. Climacteric 6 2 (Jun 2003) 140-145
19. Marino R. Short-term effects of raloxifene on the main anti-coagulant system in postmenopausal women. Cicinelli E, Scaraggi FA, Galatino P, Lapecorella M, De Mitrio V, editors. Abst. NO P0934. Supp 1. Thromb Haemost. Ref Type: Generic.
20. Cosman F., Baz-Hecht M., Cushman M., Vardy M.D., Cruz J.D., Nieves J.W., et al. Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature. Thromb Res 116 1 (2005) 1-13
21. Erman M., Abali H., Oran B., Haznedaroglu I.C., Canpinar H., Kirazli S., et al. Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state?. Ann Oncol 15 11 (Nov 1 2004) 1622-1626
22. Meade T.W., Mellows S., Brozovic M., Miller G.J., Chakrabarti R.R., North W.R., et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 2 8506 (Sep 6 1986) 533-537
23. Tsai A.W., Cushman M., Rosamond W.D., Heckbert S.R., Tracy R.P., Aleksic N., et al. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med 113 8 (Dec 1 2002) 636-642
24. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995 Jan 18;273(3):199-208.
25. Nickelsen T., Creatsas G., Rechberger T., Depypere H., Erenus M., Quail D., et al. Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study. Climacteric 4 4 (Dec 2001) 320-331
26. Walsh B.W., Kuller L.H., Wild R.A., Paul S., Farmer M., Lawrence J.B., et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA, J Am Med Assoc 279 18 (May 13 1998) 1445-1451
27. de Valk-de Roo G.W., Stehouwer C.D., Meijer P., Mijatovic V., Kluft C., Kenemans P., et al. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: a 2-year, placebo-controlled study. Arterioscler Thromb Vasc Biol 19 12 (Dec 1999) 2993-3000
28. Azevedo G.D., Franco R.F., Baggio M.S., Maria de Oliveira Maranhao T., and Silva de Sa M.F. Procoagulant state after raloxifene therapy in postmenopausal women. Fertil Steril 84 6 (Dec 2005) 1680-1684
29. Bladbjerg E.M., Madsen J.S., Kristensen S.R., Abrahamsen B., Brixen K., Mosekilde L., et al. Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. J Thromb Haemost 1 6 (Jun 2003) 1208-1214